Financial Survey: Orthopediatrics (KIDS) & Obalon Therapeutics (OBLN)

Orthopediatrics (NASDAQ: KIDS) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Orthopediatrics and Obalon Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orthopediatrics 0 0 4 0 3.00
Obalon Therapeutics 1 0 2 0 2.33

Orthopediatrics presently has a consensus price target of $23.67, indicating a potential upside of 23.91%. Obalon Therapeutics has a consensus price target of $12.00, indicating a potential upside of 51.90%. Given Obalon Therapeutics’ higher probable upside, analysts plainly believe Obalon Therapeutics is more favorable than Orthopediatrics.

Profitability

This table compares Orthopediatrics and Obalon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orthopediatrics N/A N/A N/A
Obalon Therapeutics -459.54% -59.77% -47.02%

Institutional and Insider Ownership

44.1% of Obalon Therapeutics shares are held by institutional investors. 16.4% of Obalon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Orthopediatrics and Obalon Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orthopediatrics N/A N/A N/A N/A N/A
Obalon Therapeutics $3.39 million 40.64 -$20.46 million ($1.99) -3.97

Orthopediatrics has higher earnings, but lower revenue than Obalon Therapeutics.

Summary

Orthopediatrics beats Obalon Therapeutics on 5 of the 9 factors compared between the two stocks.

About Orthopediatrics

OrthoPediatrics Corp. is a United States-based medical device company. The Company designs, develops and commercializes orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients. It operates through the OrthoPediatrics segment, which designs, develops and markets implants and devices for children with orthopedic problems. Its products include RESPONSE Spinal Deformity System, PediNail Intramedullary Nail System, PediLoc Plating Systems, ACL Reconstruction System, Locking Cannulated Blade (LCB) plate system, Locking Proximal Femur (LPF) plate system, PediFlex Flexible Nailing System, PediFrag, PediLoc Extension Osteotomy Plate (PLEO), PediLoc Femur Locking Plate System, PediLoc Tibia Locking Plate System, PediPlates system and Spica Table. It markets over 20 surgical systems that serve approximately three categories within pediatric orthopedic market, including trauma and deformity, complex spine and anterior cruciate ligament reconstruct

About Obalon Therapeutics

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

What are top analysts saying about Orthopediatrics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orthopediatrics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit